Using a candidate gene approach we recently identified frequent methylation of the RASSF2 gene associated with poor overall survival in Ewing sarcoma (ES). To identify effective biomarkers in ES on a genome-wide scale, we used a functionally proven epigenetic approach, in which gene expression was induced in ES cell lines by treatment with a demethylating agent followed by hybridization onto high density gene expression microarrays. After following a strict selection criterion, 34 genes were selected for expression and methylation analysis in ES cell lines and primary ES. Eight genes (CTHRC1, DNAJA4, ECHDC2, NEFH, NPTX2, PHF11, RARRES2, TSGA14) showed methylation frequencies of > 20% in ES tumors (range 24-71%), these genes were expressed in human bone marrow derived mesenchymal stem cells (hBMSC) and hypermethylation was associated with transcriptional silencing. Methylation of NPTX2 or PHF11 was associated with poorer prognosis in ES. In addition, six of the above genes also showed methylation frequency of > 20% (range 36-50%) in osteosarcomas. Identification of these genes may provide insights into bone cancer tumorigenesis and development of epigenetic biomarkers for prognosis and detection of these rare tumor types.

Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma / A. Alholle, A.T. Brini, S. Gharanei, S. Vaiyapuri, E. Arrigoni, A. Dallol, D. Gentle, T. Kishida, T. Hiruma, S. Avigad, R. Grimer, E.R. Maher, F. Latif. - In: EPIGENETICS. - ISSN 1559-2294. - 8:11(2013 Nov), pp. 1198-1204.

Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma

A.T. Brini
Secondo
;
E. Arrigoni;
2013

Abstract

Using a candidate gene approach we recently identified frequent methylation of the RASSF2 gene associated with poor overall survival in Ewing sarcoma (ES). To identify effective biomarkers in ES on a genome-wide scale, we used a functionally proven epigenetic approach, in which gene expression was induced in ES cell lines by treatment with a demethylating agent followed by hybridization onto high density gene expression microarrays. After following a strict selection criterion, 34 genes were selected for expression and methylation analysis in ES cell lines and primary ES. Eight genes (CTHRC1, DNAJA4, ECHDC2, NEFH, NPTX2, PHF11, RARRES2, TSGA14) showed methylation frequencies of > 20% in ES tumors (range 24-71%), these genes were expressed in human bone marrow derived mesenchymal stem cells (hBMSC) and hypermethylation was associated with transcriptional silencing. Methylation of NPTX2 or PHF11 was associated with poorer prognosis in ES. In addition, six of the above genes also showed methylation frequency of > 20% (range 36-50%) in osteosarcomas. Identification of these genes may provide insights into bone cancer tumorigenesis and development of epigenetic biomarkers for prognosis and detection of these rare tumor types.
functional epigenomics; 5-aza-2 '-deoxycytidine; Ewing sarcoma; Osteosarcoma; bone tumors
Settore BIO/14 - Farmacologia
nov-2013
Article (author)
File in questo prodotto:
File Dimensione Formato  
2013 Epigenetics - Abdullah et al..pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.46 MB
Formato Adobe PDF
1.46 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/226295
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 33
social impact